Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immucor -- Ignore unavailable to you. Want to Upgrade?

To: Thomas Kirwin who wrote (250)	11/12/1998 8:59:00 AM
From: Mason Barge	Respond to of 422

This news made me feel, er, slightly better. :-)) This ought to, what, roughly double quarterly earnings not counting the 2.4MM in sales deferred until next quarter. 'Bout time. If the stock doesn't rise on this, I don't know what it'll take. <<NORCROSS, Ga., Nov. 12 /PRNewswire/ -- Immucor, Inc. (Nasdaq: BLUD), a leading provider of blood bank reagents and related products, today announced that it will surpass expectations for instrument purchase commitments for the three months ending November 30, 1998. Commenting on second quarter orders, Edward L. Gallup, President and CEO of Immucor, Inc. said, "We are very pleased with the performance of our capital sales force in the quarter following the United States Food and Drug Administrations clearance to market the ABS2000. In-house orders for the entire instrument family will be $4.0 million which is a dramatic increase compared to previously disclosed projections of $1.6 million. Some early purchase orders require an evaluation before customer acceptance. The Company expects all placements to be accepted, but has elected to defer revenue recognition until the third quarter. Booked second quarter sales will be $1.6 million and will result in a $2.4 million dollar third quarter sales backlog."